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Background: The CHADS2 and HASBLED scores are important tools to predict the risks of stroke and bleeding, respectively, in patients with atrial 
fibrillation (AF) and to help guide decisions regarding the use of antithrombotic therapy.
Methods: The ARISTOTLE trial randomized 18,201 patients to apixaban 5 mg twice daily or warfarin. The safety, efficacy, and balance of safety and 
efficacy were compared across patient risk categories classified by CHADS2 and HASBLED scores.
Results: Irrespective of the risk of stroke (CHADS2 0-1, 2, or ≥3), there were consistently lower rates of stroke or systemic embolism, major 
bleeding, mortality, and intracranial bleeding with apixaban than with warfarin (Table). Irrespective of the risk of bleeding (HASBLED 0-2, 3, or ≥4), 
patients assigned to apixaban had lower rates of ISTH major bleeding (P interaction=0.66). The 50% reduction in intracranial hemorrhage with 
apixaban versus warfarin was similar across CHADS2 (P interaction=0.18) and HASBLED (P interaction=0.44) categories. The absolute benefits of 
apixaban were greater in patients with higher CHADS2 or HASBLED scores.
Conclusions: The benefits of apixaban compared with warfarin in reducing stroke or systemic embolism, major and intracranial bleeding, and all-
cause mortality are consistent across stroke and bleeding risks levels as assessed by the CHADS2 and HASBLED scores.
Table. Stroke, systemic embolism and major bleeding, and all-cause mortality according to CHADS2 and HASBLED categories 
Endpoint
CHADS2 
Category
HR (95% CI)
P 
Interaction
HASBLED 
Score
HR (95% CI)
P 
Interaction
Stroke or systemic embolism 0.45 0.783
0-1 0.85 (0.57, 1.27) 0-2 0.97 (0.52, 1.82)
2 0.90 (0.66, 1.23) 3 0.70 (0.49, 1.02)
≥3 0.70 (0.54, 0.91) ≥4 0.80 (0.64, 0.99)
ISTH major bleeding 0.45 0.664
0-1 0.59 (0.44, 0.78) 0-3 0.68 (0.42, 1.11)
2 0.76 (0.60, 0.96) 3 0.73 (0.55, 0.97)
≥3 0.70 (0.56, 0.88) ≥4 0.68 (0.57, 0.81)
All-cause mortality 0.49 0.32
0-1 0.96 (0.76, 1.22) 0-2 0.84 (0.61, 1.15)
2 0.89 (0.74, 1.07) 3 1.04 (0.84, 1.29)
≥3 0.87 (0.73, 1.03) ≥4 0.85 (0.74, 0.98)
